Composition for preventing gray hair, promoting black hair and preventing, improving or treating vitiligo or hypochromatism comprising fructose 1,6-bisphosphate or salt, solvate, stereoisomer or hydrate thereof as active ingredient
Fructose 1,6-bisphosphate derivatives enhance melanin production, addressing the ineffectiveness of existing treatments for gray hair and vitiligo by promoting black hair and treating depigmentation.
Patent Information
- Application Number
- KR1020210064571
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-19
- Filing Date
- 2021-05-20
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-05-20
AI Technical Summary
Existing compositions, such as essential oils from lotus flowers, do not effectively prevent gray hair or treat vitiligo or hypopigmentation, as they do not significantly affect melanin formation.
A composition comprising fructose 1,6-bisphosphate or its salts, solvates, stereoisomers, or hydrates is used to promote melanin production, preventing gray hair and treating vitiligo or hypopigmentation.
Fructose 1,6-bisphosphate or its derivatives effectively increase intracellular melanin content, preventing white hair and promoting black hair, and can be used to treat vitiligo or hypopigmentation.
Smart Images

Figure 112021057811313-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present specification discloses a composition for preventing gray hair, promoting black hair, and preventing, improving, or treating vitiligo or hypopigmentation, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. Background Technology
[0002] Gray hair refers to the phenomenon of hair, such as scalp hair, eyebrows, and eyelashes, becoming grayish or white. The mechanism of gray hair development is known to be caused by a decrease in the number of melanocytes (cells that produce melanin pigment) within the hair follicle, which prevents the transport of melanin to surrounding keratinocytes, resulting in a pigment deficiency. Pigmentation in scalp and body hair requires the presence of melanocytes in the hair bulb of the hair follicle. Melanin produced by these melanocytes is transferred to keratinocytes to form the hair stalk, which creates pigmented strands of hair or body hair. This structure is known as the "follicular pigmentation unit." Therefore, the normal cycle of melanocytes in human hair follicles requires the presence of melanocyte precursors that can be periodically activated to regenerate the follicular pigmentation unit located at the top of the hair follicle.
[0003] Meanwhile, vitiligo is an acquired depigmentary disorder characterized by the appearance of depigmented patches of various sizes and shapes on the skin due to the loss of melanocytes. Vitiligo affects 1–2% of the global population and can be a cosmetic issue for patients, as well as cause serious psychological problems, such as difficulties in interpersonal relationships. Hypochromatism is a condition histologically similar to vitiligo, showing a state where melanin in the lesions is almost completely lost; however, unlike vitiligo where pigment is destroyed naturally, hypochromatism is caused by skin conditions such as atopic dermatitis or inflammatory dermatitis.
[0004] Korean Patent Publication No. 10-2009-0076536 discloses an essential oil extracted from lotus flowers for treating vitiligo and gray hair. However, since the aforementioned essential oil does not significantly affect melanin formation, it does not produce a noticeable effect. Accordingly, there is a need for further research and development on compositions that provide superior protection against gray hair, promote black hair, and treat vitiligo or hypopigmentation. Prior art literature
[0005] Republic of Korea Published Patent Application No. 10-2009-0076536 The problem to be solved
[0006] The present disclosure was devised to solve the above-mentioned problems. As a result of repeated research on substances useful for preventing gray hair, promoting black hair, and preventing, improving, or treating vitiligo or hypopigmentation, the inventors discovered that fructose 1,6-bisphosphate or its salts, solvates, stereoisomers, or hydrates exhibit excellent efficacy, thereby completing the present invention. Accordingly, the objective of the present disclosure is to provide a composition for preventing gray hair, promoting black hair, and preventing, improving, or treating vitiligo or hypopigmentation. means of solving the problem
[0007] To achieve the objectives of the above-described disclosure, the present disclosure provides a composition for preventing gray hair, promoting black hair, and preventing, improving, or treating vitiligo or hypopigmentation, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. Effects of the invention
[0008] According to the present disclosure, fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate has the advantage of excellent efficacy in preventing gray hair, promoting black hair, and preventing, improving, or treating vitiligo or hypopigmentation. Brief explanation of the drawing
[0009] Figure 1 is a graph showing the melanin synthesis-promoting effect according to the concentration of fructose 1,6-bisphosphate in human normal melanocytes. Figure 2 is an image showing the melanin synthesis-promoting effect according to the concentration of fructose 1,6-bisphosphate in normal human melanocytes. Figure 3 is an image showing the results of the evaluation of the efficacy of fructose 1,6-bisphosphate trisodium salt in preventing gray hair and promoting black hair in human hair follicles. Specific details for implementing the invention
[0010] The terms used in this specification have been selected to be as widely used as possible, taking into account their functions in the present disclosure; however, these terms may vary depending on the intent of those skilled in the art, case law, or the emergence of new technologies. Additionally, in specific cases, terms have been selected at the applicant's discretion, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, terms used in this disclosure should be defined not merely by their names, but based on their meanings and the overall content of the present disclosure.
[0011] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the present invention pertains. Terms generally understood should be interpreted as having the same meaning as they have in the context of the relevant technology and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this disclosure.
[0012] Numerical ranges include the numerical values defined in this disclosure. All maximum numerical limits given throughout this specification include all lower numerical limits as clearly written. All minimum numerical limits given throughout this specification include all higher numerical limits as clearly written. All numerical limits given throughout this specification will include all better numerical ranges within a wider numerical range, as clearly written.
[0013] As used herein, the words “comprising,” “having,” and “containing” are inclusive or open and do not exclude additional unmentioned elements or method steps. As used herein, the term “or combinations thereof” refers to any permutation and combination of the items listed prior to the said term. For example, “A, B, C, or combinations thereof” is intended to include at least one of A, B, C, AB, AC, BC, or ABC, and, where order is important in a particular context, BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. With this example, combinations containing repetitions of one or more items or terms, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, etc., are explicitly included. A person skilled in the art will understand that, unless otherwise obvious from the context, there is typically no limit to the number of items or terms in any combination.
[0014] The present disclosure will be described in detail below with reference to the embodiments and drawings. However, it is obvious that the present invention is not limited by the following embodiments and drawings.
[0015] In one aspect, the present disclosure provides a composition for preventing gray hair or promoting black hair, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. In one aspect, the present disclosure provides a composition for preventing, improving, or treating vitiligo or hypopigmentation, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. In one aspect, the present disclosure provides a composition for promoting melanin production, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient.
[0016] The above-mentioned fructose 1,6-bisphosphate (FBP) is an intermediate produced during glycolysis in vivo and is known to have the effect of protecting cells from tissue damage induced during reperfusion following hypoxia or ischemia in the heart or brain[ Gastroenterology [ , (1990) 98: 117-126]. It has also been reported to inhibit the production of nitric oxide generated by endotoxins in mouse macrophages[ Biochemical and Biophysical Research Communication [, (1998) 243:683-687]. Although the exact mechanism of these actions of fructose 1,6-bisphosphate within cells is not yet known, based on the results to date, fructose 1,6-bisphosphate is an important substance involved in metabolic processes that controls or regulates various reactions occurring within cells.
[0017] As the fructose 1,6-bisphosphate of the present disclosure, any fructose 1,6-bisphosphate that is commonly available can be used, and may be used in the form of pure fructose 1,6-bisphosphate as well as derivatives of fructose 1,6-bisphosphate. These derivatives may be in the form of salts. The salts may be used in the form of salts that are cosmetic, food, and / or pharmaceutically acceptable, and acid addition salts formed by free acids are useful as such salts. Acid addition salts are obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromide, hydroiodide, nitrous acid, phosphoric acid, etc., aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates and alkandioates, aromatic acids, aliphatic and aromatic sulfonic acids, etc., non-toxic organic acids such as trifluoroacetic acid, acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid, etc. The above acid addition salt can be prepared by conventional methods, for example, by dissolving a compound in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile, etc., adding an organic acid or an inorganic acid to produce a precipitate, filtering and drying it, or by vacuum distilling the solvent and excess acid, drying it, and crystallizing it under an organic solvent.
[0018] Types of salts that are non-toxic in cosmetics, food science, and / or pharmaceuticals include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphate chloride, bromides, iodides, fluorides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caprates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, malieates, butyne-1,4-dioate, hexane-1,6-dioate, benzoates, chlorobenzoates, methyl benzoates, dinitrobenzoates, and hydroxybenzoates. Includes methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, etc.
[0019] In addition, the above salt may be a metal salt prepared using a base. An alkali metal or alkaline earth metal salt is obtained, for example, by dissolving a compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. Examples of metal salts include barium salt, dibarium salt, sodium salt, disodium salt, tetrasodium salt, potassium salt, calcium salt, dicalcium salt, dimagnesium salt, and tricyclohexylamine salt. Additionally, a corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable nitrate (e.g., silver nitrate).
[0020] In addition, the composition of the present disclosure may include not only the salt of fructose 1,6-bisphosphate in the form of a derivative thereof, but also solvates, stereoisomers, hydrates, etc. that can be prepared therefrom.
[0021] The term “solvate” refers to a compound of the present disclosure comprising stoichiometric or non-stoichiometric amounts of solvent bound by non-covalent intermolecular forces. Preferred solvents thereof include volatile, non-toxic, and / or solvents suitable for administration to humans.
[0022] The term “stereoisomer” refers to an isomer that has the same molecular formula and the method of connecting constituent atoms, but differs in the spatial arrangement of the atoms. Such stereoisomers may be diasteromers or enantiomers. Diasteromers refer to stereoisomers that are not mirror images of each other and can be classified into cis and trans isomers due to differences in the spatial arrangement of atoms. Enantiomers refer to isomers that do not overlap with their mirror images, much like the relationship between a left hand and a right hand, and are also called optical isomers. Enantiomers are classified as R (Rectus: clockwise) and S (Sinister: counterclockwise) when there are four or more different substituents on the chiral central carbon. These isomers and mixtures thereof are also included in the present disclosure.
[0023] The term “hydrate” means a compound containing stoichiometric or non-stoichiometric amounts of water bound by non-covalent intermolecular forces. The hydrate may contain at least 1 equivalent, preferably 1 to 5 equivalents of water. Such a hydrate may be prepared by crystallizing the compound of the present disclosure from water or a solvent containing water.
[0024] The above “active ingredient” refers to a component exhibiting the intended activity or a component capable of exhibiting activity together with a carrier that is inactive in itself. The above “composed as an active ingredient” may mean including as a component exhibiting efficacy in preventing gray hair, promoting black hair, and / or preventing, improving, or treating vitiligo or hypopigmentation.
[0025] The composition of the present disclosure can increase the intracellular melanin content, prevent the induction of white hair in advance, and promote the induction of black hair, and can be usefully used as a composition for the prevention, improvement, or treatment of vitiligo or hypopigmentation.
[0026] According to one embodiment of the present disclosure, the daily dosage of the fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may be greater than 10 mg / kg and less than 10,000 mg / kg, and the daily dosage may vary depending on the age, gender, and weight of the subject to be treated, the specific disease or pathological condition of the subject, the severity of the disease or pathological condition, the route of administration, etc., and the determination of the dosage based on these factors is within the level of a person skilled in the art. More specifically, the above daily dosage is greater than 10 mg / kg, 11 mg / kg or more, 12 mg / kg or more, 13 mg / kg or more, 14 mg / kg or more, 15 mg / kg or more, 16 mg / kg or more, 17 mg / kg or more, 18 mg / kg or more, 19 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more, 60 mg / kg or more, 70 mg / kg or more, 80 mg / kg or more, 90 mg / kg or more, or 100 mg / kg or more; less than 10,000 mg / kg; It may be 9,000 mg / kg or less, 8,000 mg / kg or less, 7,000 mg / kg or less, 6,000 mg / kg or less, 5,000 mg / kg or less, 4,000 mg / kg or less, 3,000 mg / kg or less, 2,000 mg / kg or less, 1,000 mg / kg or less, 900 mg / kg or less, 800 mg / kg or less, 700 mg / kg or less, 600 mg / kg or less, 500 mg / kg or less, 400 mg / kg or less, 300 mg / kg or less, 200 mg / kg or less, or 100 mg / kg or less, but is not limited thereto. The above application may be divided into one or several times per day. For example, it may be applied 2 to 24 times a day, 1 to 2 times every 3 days, 1 to 6 times a week, 1 to 10 times every 2 weeks, 1 to 15 times every 3 weeks, 1 to 3 times every 4 weeks, or 1 to 12 times a year.The term “application” above means providing the composition to a subject of application by any appropriate method, and includes administration, application, absorption, and ingestion. In this case, the subject of application refers to any animal, such as a human, monkey, dog, goat, pig, or rat, to which the composition can be applied.
[0027] As a method of application, the fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may be administered in various oral and parenteral formulations. When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
[0028] Solid dosage forms for oral administration include, for example, tablets, pills, powders, granules, and capsules. These solid dosage forms are prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include, for example, suspensions, liquids, emulsions, and syrups. These liquid dosage forms may contain various excipients, for example, humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
[0029] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, and emulsions. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. A composition containing the above-mentioned fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient may be administered parenterally, and parenteral administration may be performed by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. In this case, to formulate a parenteral administration formulation, the above-mentioned fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may be mixed with water along with a stabilizer or buffer to prepare a solution or suspension, which may then be prepared in an ampoule or vial unit dosage form. The above composition may be sterilized and / or contain adjuvants such as preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated according to conventional mixing, granulation, or coating methods.
[0030] According to one embodiment of the present disclosure, the content of fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may vary depending on the formulation, use, frequency of application, and route of application. In particular, when the composition of the present disclosure is prepared as a parenteral formulation such as an injection, or as an oral formulation such as food, tablet, or syrup, the content of the active ingredient of the present disclosure may vary depending on the intestinal absorption rate, digestion rate, etc. of the composition. However, when the composition of the present disclosure is prepared as a topical skin preparation and applied topically, considering the daily application amount, it may be applied in an amount greater than 60 mg and less than 60,000 mg for a subject weighing 60 kg. Assuming a daily application amount of 100 g, the content of the active ingredient of the present disclosure may be contained in an amount greater than 0.06 weight% and less than 60 weight% with respect to the total weight of the composition.
[0031] According to one embodiment of the present disclosure, the fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may be contained in an amount greater than 0.06 wt% and less than 60 wt% based on the total weight of the composition. More specifically, greater than 0.06 wt%, 0.07 wt% or more, 0.08 wt% or more, 0.09 wt% or more, 0.1 wt% or more, 0.2 wt% or more, 0.3 wt% or more, 0.4 wt% or more, 0.5 wt% or more, or 0.6 wt% or more; It may be less than 60 wt%, 59 wt% or less, 58 wt% or less, 57 wt% or less, 56 wt% or less, 55 wt% or less, 54 wt% or less, 53 wt% or less, 52 wt% or less, 51 wt% or less, 50 wt% or less, 40 wt% or less, 30 wt% or less, 20 wt% or less, 10 wt% or less, 9 wt% or less, 8 wt% or less, 7 wt% or less, 6 wt% or less, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less, 0.9 wt% or less, 0.8 wt% or less, 0.7 wt% or less, or 0.6 wt% or less, but is not limited thereto. Preferably, the fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may be contained in an amount of 1% to 10% by weight based on the total weight of the composition.
[0032] According to one embodiment of the present disclosure, the composition promotes the production of melanin pigment by melanocytes. More specifically, the composition stimulates inactive melanocytes or pigment-forming cells present in the skin or hair follicles to promote differentiation, proliferation, and migration, and to produce melanin. By thus promoting the production of melanin pigment, the composition of the present disclosure can prevent the induction of gray hair and promote the induction of black hair, and can be usefully used as a composition for the prevention, improvement, or treatment of vitiligo or hypopigmentation.
[0033] According to one embodiment of the present disclosure, the gray hair is caused by aging. The causes of gray hair include the loss of stem cells of melanocytes, a decrease in the activity of melanocytes, and aging, and the gray hair in the present disclosure is particularly caused by aging.
[0034] According to one embodiment of the present disclosure, the composition may be a topical skin composition. The term “skin” refers to tissue covering the body surface of an animal and is a concept in the broadest sense that includes not only tissue covering the body surface, such as the face or body, but also the scalp and hair.
[0035] According to one embodiment of the present disclosure, the composition may be a cosmetic composition. The cosmetic composition may be formulated by conventional methods. In formulating, reference may be made to the contents disclosed in the International Cosmetic Ingredient Dictionary (INCI) published by The Cosmetic, Toiletry and Fragrance Association.
[0036] Specifically, the composition may be formulated into a hair rinse, shampoo, hair conditioner, hair pack, hair oil, hair treatment, hair cream, hair lotion, hair gel, hair essence, hair spray, hair serum, hair ampoule, makeup remover, cleanser, lotion (softening lotion, nourishing lotion), emulsion, cream (nourishing cream, massage cream), pack, essence, etc. The formulation may be a rinse-off type or a wash-off type, meaning that the formulation is rinsed off after application to the hair or scalp; or a leave-on or leave-in type, meaning that the formulation remains on the hair or scalp after application.
[0037] The above composition may additionally contain, as needed, auxiliary agents commonly used in the fields of cosmetics or dermatology, such as fatty substances, organic solvents, solvents, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, preservatives, pH adjusters, water, ionic or nonionic emulsifiers, fillers, metal ion blocking agents, chelating agents, preservatives, blockers, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, and any other ingredients commonly used in cosmetics, depending on the quality or function of the final product.
[0038] According to one embodiment of the present disclosure, the composition may be a food composition. The fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate may be added directly to food or used together with other food or food ingredients, and may be appropriately used according to conventional methods. The amount of the active ingredient may be appropriately determined according to its intended use (for prevention or improvement).
[0039] The above food composition may be a health functional beverage composition, and the beverage composition has no special restrictions on other ingredients other than containing the above compound as an essential ingredient in the indicated proportion, and may contain various flavoring agents or natural carbohydrates, etc. as additional ingredients as in ordinary beverages. Examples of the above-mentioned natural carbohydrates are monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be advantageously used.
[0040] According to one embodiment of the present disclosure, the composition may be a pharmaceutical composition. The pharmaceutical composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and other therapeutically useful substances. As a method of application of the pharmaceutical composition, it may be administered in various oral and parenteral formulations, and specific details are as described above.
[0041] In another aspect, the present disclosure provides the use of fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate in preparing a composition for preventing gray hair or promoting black hair.
[0042] In another aspect, the present disclosure provides the use of fructose 1,6-bisphosphate or its salts, solvates, stereoisomers, or hydrates in preparing compositions for the prevention, improvement, or treatment of vitiligo or hypopigmentation.
[0043] In another aspect, the present disclosure provides the use of fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate in preparing a composition for promoting melanin production.
[0044] In another aspect, the present disclosure provides a method for preventing gray hair or promoting black hair, comprising the step of applying a composition comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient to an individual in need thereof.
[0045] In another aspect, the present disclosure provides a method for preventing, improving, or treating vitiligo or hypopigmentation, comprising the step of applying a composition comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient to an individual in need thereof.
[0046] In another aspect, the present disclosure provides a method for promoting melanin production, comprising the step of applying a composition comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient to an individual in need thereof.
[0047] In another aspect, the present disclosure provides fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate for use in preventing gray hair or promoting black hair.
[0048] In another aspect, the present disclosure provides fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate for use in preventing, improving, or treating vitiligo or hypopigmentation.
[0049] In another aspect, the present disclosure provides fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate for use in promoting melanin production.
[0050] {Example}
[0051] The present disclosure will be explained in detail below through examples. However, the following examples are merely illustrative to aid in the overall understanding of the present disclosure, and the content of the present disclosure is not limited to the following examples.
[0052] <Test Example 1> Evaluation of the melanin synthesis-promoting effect of fructose 1,6-bisphosphate according to concentration in human normal melanocytes
[0053] 1. Evaluation Method
[0054] Normal human epidermal melanocytes (GIBCO TM Fructose 1,6-bisphosphate was treated to cells (ThermoFisher Scientific, USA) at concentrations of 0 ppm (untreated group), 0.1 ppm, 1 ppm, 10 ppm, and 100 ppm, respectively, and cultured for 6 days. After culture, the cells were dissolved in 1N NaOH, and the absorbance was measured at 475 nm. The amount of melanin produced was expressed as a relative percentage, with the absorbance of the untreated group (not treated with fructose 1,6-bisphosphate) set to 100 percent (%). An increase in absorbance indicates a higher melanin content. The results are shown in Figure 1. Meanwhile, e-tube images of melanocytes dissolved in NaOH are shown in Figure 2.
[0055] 2. Evaluation Results
[0056] From Figures 1 and 2, it was confirmed that fructose 1,6-bisphosphate exhibited melanin production-promoting efficacy in melanocytes, and in particular, the efficacy increased rapidly in the 100 ppm treatment group.
[0057] <Test Example 2> Evaluation of the efficacy of fructose 1,6-bisphosphate trisodium salt in preventing gray hair and promoting black hair in human hair follicles
[0058] 1. Separation of human hair follicles
[0059] After performing a hair follicle transplant on a 45-year-old male with hair loss, occipital scalp tissue was obtained. Hair follicle samples were isolated from the obtained occipital scalp tissue using a microscope. For experimental application, a total of 3 groups of hair follicle samples (i.e., 15 samples) were prepared, with 5 samples per group.
[0060] 2. Hair follicle culture
[0061] 500 μl of culture medium was dispensed into a 24-well plate (Nunc, Wiesbaden, Germany), and 5 samples were cultured per well. William's E medium (Gibco, NY, USA) containing 2 mM L-glutamine (PAA, Coelbe, Germany), 10 μg / ml insulin, 10 ng / ml hydrocortisone (Sigma, St Louis, MO), 0.1% fungizone (Gibco, NY, USA), 10 μg / ml streptomycin, and 100 U / ml penicillin (Gibco, NY, USA) was used as the culture medium. Then, hydrogen peroxide and fructose 1,6-bisphosphate trisodium (FBP-Na3H) were simultaneously treated at 1000 μM and 100 ppm, respectively, and cultured for 3 days. Meanwhile, for comparison, a group treated with only hydrogen peroxide (H2O2) at 1000 μM was used, and as a control group, a group not treated with either hydrogen peroxide or fructose 1,6-bisphosphate trisodium salt was used.
[0062] 3. Observation of melanin pigment using Fontana-Mason staining
[0063] After drug treatment, the tissues were fixed with formalin, washed stepwise according to standard tissue processing, dehydrated with alcohol and xylene, and embedded in paraffin. 8 µm tissue sections were prepared using a microtome (Leica RM 2145, Germany), stained with Fontana Masson, and the hair follicles were photographed using a stereomicroscope (Dongwon CNS, Korea). The images are shown in Figure 3.
[0064] 4. Evaluation Results
[0065] From Figure 3, it was confirmed that fructose 1,6-bisphosphate trisodium salt has an anti-gray hair effect by promoting melanin production in human hair follicles and simultaneously preventing the reduction of melanin production in the hair bulb caused by damage from hydrogen peroxide, etc.
[0066] Examples of formulations of a composition according to one aspect of the present invention are described below, but they can be applied to various other formulations, and this is not intended to limit the present invention but merely to provide a specific description.
[0067] [Formulation Example 1] Shampoo
[0068] Shampoo was prepared by a conventional method according to the composition listed in Table 1 below.
[0069] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 Ammonium lauryl sulfate (ALS) 20.0 Ammonium laureth sulfate (ALES) 20.0 Cocaamide Mipha Appropriate amount Disodium EDTA 0.03 Carbomer Appropriate amount ethanol Appropriate amount Cocamide propyl betaine 6.0 Dimethicone (50%) 2.0 Dimethicone (70%) 2.0 DL-Panthenol Appropriate amount Tocopheryl acetate Appropriate amount Triethanolamine Appropriate amount menthol Appropriate amount Methylchloroisothiazolinone Methylisothiazolinone Mixture (MC / IMI) 0.03 Methylparaben Appropriate amount Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0070] [Formulation Example 2] Hair rinse
[0071] A hair rinse was prepared using a conventional method according to the composition listed in Table 2 below.
[0072] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 Propylene glycol 2.0 Cetyltrimethylammonium chloride 1.0 Cetyl alcohol 3.0 Stearyl alcohol 3.0 mineral oil 0.5 Cytic acid 0.2 polydimethylsiloxane 1.0 Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0073] [Formulation Example 3] Softening lotion
[0074] Softening lotion was prepared by a conventional method according to the composition listed in Table 3 below.
[0075] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 ethanol 10.0 Triethanolamine 0.1 Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0076] [Formulation Example 4] Nourishing lotion
[0077] A nourishing lotion was prepared using a conventional method according to the composition listed in Table 4 below.
[0078] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 Beeswax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalan 5.0 Caprylic / Capric Triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0079] [Formulation Example 5] Nourishing Cream
[0080] A nourishing cream was prepared using a conventional method according to the composition listed in Table 5 below.
[0081] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalan 5.0 Caprylic / Capric Triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0082] [Formulation Example 6] Massage cream
[0083] A massage cream was prepared using a conventional method according to the composition listed in Table 6 below.
[0084] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalan 5.0 Caprylic / Capric Triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0085] [Formulation Example 7] Pack
[0086] A pack was manufactured using a conventional method according to the composition listed in Table 7 below.
[0087] ingredient Content (weight%) Fructos 1,6-bisphosphate 5 polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 allantoin 0.1 ethanol 5.0 nonylphenyl ether 0.3 Preservatives, colors, and flavors Appropriate amount purified water Remaining amount
[0088] [Formulation Example 8] Powder
[0089] A powder was prepared using a conventional method according to the composition listed in Table 8 below.
[0090] ingredient Content (g) Fructos 1,6-bisphosphate 5 lactose 1
[0091] [Formulation Example 9] Tablet
[0092] Tablets were prepared by conventional methods according to the composition listed in Table 9 below.
[0093] ingredient Content (mg) Fructos 1,6-bisphosphate 500 corn starch 50 lactose 50 magnesium stearate 2
[0094] [Formulation Example 10] Capsule
[0095] A capsule was prepared using a conventional method according to the composition listed in Table 10 below. After mixing the ingredients of the composition below, the capsule was prepared by filling it into a gelatin capsule according to a conventional method for preparing capsules.
[0096] ingredient Content (mg) Fructos 1,6-bisphosphate 600 corn starch 100 lactose 100 magnesium stearate 2
[0097] [Formulation Example 11] Drink
[0098] A drink was prepared using a conventional method according to the composition listed in Table 11 below.
[0099] ingredient Content (g) Fructos 1,6-bisphosphate 0.1 glucose 10 Citric acid 2 purified water 100
[0100] In various embodiments, the present disclosure relates to at least the following embodiments and includes at least the following embodiments.
[0101] [Mode 1] A composition for preventing gray hair or promoting black hair, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient.
[0102] [Mode 2] A composition for the prevention, improvement, or treatment of vitiligo or hypopigmentation, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient.
[0103] [Mode 3] A composition for promoting melanin production, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient.
[0104] [Mode 4] A composition in which, in one of embodiment 1 or embodiment 3, the daily applied amount of fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate is greater than 10 mg / kg and less than 10,000 mg / kg.
[0105] [Mode 5]A composition in one of embodiments 1 to 4, wherein the fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate is contained in an amount greater than 0.06 weight% and less than 60 weight% based on the total weight of the composition.
[0106] [Mode 6] In one of embodiments 1 to 5, the composition promotes the production of melanin pigment in melanocytes.
[0107] [Mode 7] A composition in which, in one of embodiments 1 to 6, the white hair is due to aging.
[0108] [Mode 8] A composition in one of embodiments 1 to 7, wherein the composition is a skin external application composition.
[0109] [Mode 9] A composition in one of embodiments 1 to 8, wherein the composition is a cosmetic composition.
[0110] [Mode 10] A composition in one of embodiments 1 to 9, wherein the composition is a food composition.
[0111] [Mode 11] A composition in one of embodiments 1 to 10, wherein the composition is a pharmaceutical composition.
[0112] Although the present invention has been described in relation to the preferred embodiments mentioned above, various modifications and variations are possible without departing from the essence and scope of the invention. Accordingly, the appended claims will include such modifications and variations insofar as they fall within the essence of the invention.
Claims
Claim 1 A composition for preventing gray hair or promoting black hair, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. Claim 2 A composition for the prevention, improvement, or treatment of vitiligo or hypopigmentation, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. Claim 3 A composition for promoting melanin production, comprising fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate as an active ingredient. Claim 4 A composition according to any one of claims 1 to 3, wherein the daily applied amount of fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate is greater than 10 mg / kg and less than 10,000 mg / kg. Claim 5 A composition according to any one of claims 1 to 3, wherein the fructose 1,6-bisphosphate or its salt, solvate, stereoisomer, or hydrate is contained in an amount greater than 0.06 weight% and less than 60 weight% based on the total weight of the composition. Claim 6 A composition according to any one of claims 1 to 3, wherein the composition promotes the production of melanin pigment in melanocytes. Claim 7 A composition according to claim 1, wherein the white hair is due to aging. Claim 8 A composition according to any one of claims 1 to 3, wherein the composition is a skin external application composition. Claim 9 A composition according to claim 1 or 3, wherein the composition is a cosmetic composition. Claim 10 A composition according to claim 1 or 3, wherein the composition is a food composition. Claim 11 In paragraph 2, the composition is a pharmaceutical composition.
Citation Information
Patent Citations
Composition for external applications to the skincontaining D-fructose 1,6-diphosphate or derivativesthereof to improve skin xerosis
KR1020030090367A
